Ventripoint Provides Corporate Update and Announces Shareholder Video Conference Call

(TheNewswire)

Toronto, Canada - February19, 2026 – TheNewswire - Ventripoint DiagnosticsLtd. ("Ventripoint" or the "Company")(TSXV:VPT;OTC:VPTDF), a leading provider of innovativeAI-powered cardiac diagnostic solutions, is pleased to provide acorporate update and announces a shareholder videoconferencecall.

Dear Shareholders,

Ventripoint continues to execute on its strategy toexpand commercialization of VMS+™, strengthen clinical adoption, andposition the Company for revenue growth.

Key Achievements and Advances Sincethe Last Shareholder Call

Since our last shareholder call, the Company has madeprogress across regulatory execution, commercialization planning,clinical engagement, and operational readiness, including:

Commercial and Market Development

• Continued refinement of the Company’s U.S.go-to-market approach, designed to reduce friction in the salesprocess and accelerate adoption 

• Ongoing engagement with prospective customers throughvirtual demonstrations and pipeline development activities 

• Continued alignment with distributors and partners inEurope and the United Kingdom to advance near-termopportunities 

Partnerships and Strategic Initiatives

• Continued constructive work with ASCEND Cardiovasculartoward integration discussions and commercial alignment 

• Ongoing collaboration with the Ollie Hinkle HeartFoundation, supporting U.S. system placement opportunities 

• Continued collaboration with Lishman Global to supportmanufacturing and regulatory preparation activities in China to enablemarket entry 

• Continued evaluation of potential distribution andstrategic opportunities in Asia, including active discussions with afamily office group 

• Continued development of strategy and early engagementefforts to expand VMS+™ into valvular and structural heartapplications 

Technology, Product, and Regulatory

• Continued execution on commercialization activities forVMS+™ v4.0, including customer upgrade readiness and clinicalworkflow integration planning 

• Expanded internal focus on training, installation, andcustomer support systems, including development of scalable trainingmaterials and videos 

• Strengthened internal processes supporting quality andmanufacturing readiness, building on prior successful audits 

• Continued progress on improving connectivity andintegration workflows to support adoption into routine clinicalpractice 

Corporate Development and Team Expansion

• Continued engagement with experienced commercialprofessionals, including individuals positioned to transition intoexpanded roles upon completion of financing 

• Continued engagement with governance-level candidatesto strengthen board and advisory capacity in commercialization andcapital markets 

Capital Markets and Financing

• Continued advancement of financing initiatives designedto secure growth capital while maintaining disciplined dilutionmanagement 

• Continued engagement with capital markets advisors andinvestor awareness partners to broaden visibility of the Company andits opportunity 

Shareholder Call Details

The Company will host a shareholder update call toprovide additional context on recent developments, commercializationpriorities, and upcoming milestones.

Shareholder Videoconference:

Date:                 Thursday February 26,2026

Time:                 1pm EST

Zoom Link:  https://us02web.zoom.us/j/83809648859?pwd=WsxhF4PWpwlTSjTUxsbbffsbIaIJIb.1

Meeting ID:         838 0964 8859

Passcode:         893160

Dial-in Numbers:

Dial by your location

• +1 438 809 7799 Canada

• +1 587 328 1099 Canada

• +1 647 558 0588 Canada

• +1 778 907 2071 Canada

• +1 780 666 0144 Canada

• +1 346 248 7799 US (Houston)

• +1 646 558 8656 US (New York)

• +1 669 900 9128 US (San Jose)

• +1 253 215 8782 US (Tacoma)

• +1 301 715 8592 US (Washington DC)

• +1 312 626 6799 US (Chicago)

Meeting ID: 838 0964 8859

Passcode: 893160

Find your local number:         https://us02web.zoom.us/u/kbnEnDZXPT

Closing Comments

Ventripoint continues to advance its commercializationstrategy while building the operational foundation required to supportadoption and growth. The Company appreciates the continued support ofits shareholders and looks forward to providing further updates duringthe call.

Sincerely,

Hugh MacNaught

President & CEO

hmacnaught@ventripoint.com

(604) 671-4201

Neither the TSX Venture Exchange nor its RegulationServices Provider (as that term is defined in the policies of the TSXVenture Exchange) accepts responsibility for the adequacy or accuracyof this news release.

About Ventripoint Diagnostics Ltd.

Ventripoint is a leader in the application of AI(Artificial Intelligence) to echocardiography. Ventripoint's VMSproducts are powered by its proprietary Knowledge Based Reconstructiontechnology, which is the result of a decade of development andprovides accurate volumetric cardiac measurements equivalent to MRI.This affordable, gold-standard alternative allows cardiologistsgreater confidence in the management of their patients. Providingbetter care to patients serves as a springboard and basic standard forall Ventripoint's products that guide our future developments. Inaddition, VMS+ is versatile and can be used with all ultrasoundsystems from any vendor supported by regulatory market approvals inthe U.S., Europe, and Canada.

Forward Looking Statements

This news release contains forward-looking statementsand forward-looking information within the meaning of applicablesecurities laws. The use of any of the words "expect","anticipate", "continue", "estimate","objective", "ongoing", "may","will", "project", "should","believe", "plans", "intends'' andsimilar expressions are intended to identify forward-lookinginformation or statements. The forward-looking statements andinformation are based on certain key expectations and assumptions madeby the Company. Although the Company believes that the expectationsand assumptions on which such forward-looking statements andinformation are based are reasonable, undue reliance should not beplaced on the forward-looking statements and information because theCompany can give no assurance that they will prove to becorrect.

Since forward-looking statements and informationaddress future events and conditions, by their very nature theyinvolve inherent risks and uncertainties. Actual results could differmaterially from those currently

Copyright (c) 2026 TheNewswire - All rights reserved.